We have synthesized and characterized safer new molecules that reduce fever and treat pain. Because these molecules are not opioids, they will not have risks of misuse and dependence. Animal models demonstrate analgesic (reduces pain) and antipyretic (reduces fever) properties without hepatotoxicity (liver) and nephrotoxicity (kidney) present in common over-the-counter medications, such as acetaminophen and NSAIDs (non-steroidal anti-inflammatory drugs). We have identified the molecular species responsible for the lack of liver toxicity with our compound in animal models. Additionally, immunohistochemistry studies from in vivo animal models have demonstrated how the lack of liver toxicity occurs specifically with our compound.
Currently, several biological and antibody therapies are being developed to target pain, but the US health system cannot afford and will not support more expensive therapies in future(1). Our solution is development of a novel small molecule with a markedly improved toxicity profile that treats pain and reduces fever, introducing a value product that will be low cost and therefore accessible to many patients. Both oral and intravenous infusion formulations will be developed for the treatment of acute and chronic pain and fever-reduction.
(1)Bauchner H and Fontanarose PB. ‘Health care spending in the US compared with 10 other high-income countries.’ JAMA 2018.